Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed,…
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated August 28,…
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025 20:53 ET | Source: Cognition Therapeutics, Inc. - The…
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress…
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer…
Plus Therapeutics Reports Stockholders Equityin Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
August 15, 2025 07:30 ET | Source: Plus Therapeutics Inc. HOUSTON, Aug.…
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in…
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025 16:08 ET | Source: Protara Therapeutics NEW YORK, Aug.…
